SCHEMBL7215016

SCHEMBL7215016

[CH2]CCCCNC(=S)Nc1ccccc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.66
LMNA P02545 6/20 0.62
GAA P10253 4/20 0.62
RAB9A P51151 2/20 0.60
MAOA P21397 2/20 0.60
MAOB P27338 2/20 0.60
NPC1 O15118 1/20 0.60
ALDH1A1 P00352 7/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
MEN1 O00255 3/20 0.56
MAPT P10636 4/20 0.55
ALOX12 P18054 1/20 0.55
MAPK1 P28482 1/20 0.54
POLB P06746 1/20 0.54
APOBEC3G Q9HC16 1/20 0.54
HTT P42858 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
HPGD P15428 1/20 0.54
CYP3A4 P08684 1/20 0.53
TAS2R38 P59533 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17595823 0.84 LMNA (0.79) KMT2ALMNAGAARAB9AMAOA
SCHEMBL8956279 0.83 KMT2A (0.78) KMT2ALMNAGAARAB9AMAOA
SCHEMBL11438307 0.83 KMT2A (0.77) KMT2ALMNAGAARAB9AMAOA
SCHEMBL4575974 0.82 LMNA (0.87) KMT2ALMNAGAARAB9AMAOA
SCHEMBL10667599 0.81 KMT2A (0.75) KMT2ALMNAGAARAB9AMAOA
SCHEMBL3013357 0.81 KMT2A (0.64) KMT2ALMNAGAARAB9AMAOA
SCHEMBL5445981 0.81 KMT2A (0.75) KMT2ALMNAGAARAB9AMAOA
SCHEMBL5447975 0.81 KMT2A (0.75) KMT2ALMNAGAARAB9AMAOA
SCHEMBL11068116 0.81 KMT2A (0.75) KMT2ALMNAGAARAB9AMAOA
SCHEMBL5446742 0.81 KMT2A (0.75) KMT2ALMNAGAARAB9AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6503898-B1 Administering 4,7-dibenzyl-5,6-dihydroxy-N,N*-di(m-aminobenzyl)--1,3-diazepin-2-one or salt to treat human immunodeficiency virus infection BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-01-07 US disclosed